Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome^®) to the fungal membrane

References

• Adler-Moore, J., 1994. AmBisome targeting to fungal infections. Bone Marrow Transplantation, 14 (Suppl5), S3–S7.
   Web of Science ®Google Scholar
• Adler-Moore, J., Proffitt, R.T., 1993. Development, characterizations, efficacy and mode of action of AmBisome®, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research, 3 (3), 429–450.
   Google Scholar
• Adler-Moore, J., Proffitt, R.T., 1998. AmBisome®: long circulating liposomal formulation of amphotericin B. In: Long Circulating Liposomes: Old Drugs, Therapeutics, Berlin, Heidelberg: Springer-Verlag and Landes Bioscience, Chapter 13, 185–206.
   Google Scholar
• Adler-Moore, J., et al., 2017. Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens. Journal of Liposome Research, [Epub ahead of print]. doi: 10.1080/08982104.2017.1327543
   Google Scholar
• Alcazar-Fuoli, L., Mellado, E., 2013. Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance. Frontiers in Microbiology, 3 (439), 1–6.
   Google Scholar
• Anderson, T.M., et al., 2014. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nature Chemical Biology, 10 (5), 400–406.
   PubMed Web of Science ®Google Scholar
• Balkis, M.M., et al., 2002. Mechanisms of fungal resistance: an overview. Drugs, 62 (7), 1025–1040.
   PubMed Web of Science ®Google Scholar
• Chavan, N.L., et al., 2012. Interactions of liposome carriers with infectious fungal hyphae reveals the role of β-glucans. Molecular Pharmaceutics, 9, 2489–2496.
   PubMed Web of Science ®Google Scholar
• Free, S.J., 2013. Fungal cell wall organization and biosynthesis. Advances in Genetics, 81, 33–82.
   PubMed Web of Science ®Google Scholar
• Gow, N.A.R., personal communication.
   Google Scholar
• Gray, K.C., et al., 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proceedings of the National Academy of Sciences of the United States of America, 109 (7), 2234–2239.
   PubMed Web of Science ®Google Scholar
• Groll, A.H., et al., 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental candida albicans infection of the central nervous system. The Journal of Infectious Diseases, 182, 274–282.
   PubMed Web of Science ®Google Scholar
• Khutorsky, V.E., 1992. Structures of amphotericin B-cholesterol complex. Biochimica et Biophysica Acta, 1108, 123–127.
   PubMed Web of Science ®Google Scholar
• Lestner, J.M., et al., 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphtoericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicro Agents and Chemother, 54, 3432–3441.
   PubMed Web of Science ®Google Scholar
• Lockhart, S.R., et al., 2017. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases, 64, 135–140.
   Web of Science ®Google Scholar
• McCarthy, M., et al., 2014. Mold infections of the central nervous system. The New England Journal of Medicine, 371 (2), 150–160.
   PubMed Web of Science ®Google Scholar
• Mesa-Arango, A.C., Scorzoni, L., Zaragoza, O., 2012. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Frontiers in Microbiology, 3 (286), 286.
   PubMedGoogle Scholar
• Moore, E.M., Lockwood, D.N., 2010. Treatment of visceral leishmaniasis. Journal of Global Infectious Diseases, 2 (2), 151–158.
   PubMedGoogle Scholar
• Murata, M., et al., 2009. Ion channel complex of antibiotics as viewed by NMR. Pure and Applied Chemistry, 81, 1123–1129.
   Web of Science ®Google Scholar
• Oku, N., et al., 2000. Evaluation of drug targeting strategies and liposomal trafficking. Current Pharmaceutical Design, 6, 1669–1691.
   PubMed Web of Science ®Google Scholar
• Palacios, D.S., Anderson, T.M., Burke, M.D., 2007. A post-PKS oxidation of the Amphotericin B skeleton predicted to be critical for channel formulation is not required for potent antifungal activity. Journal of the American Chemical Society, 129 (45), 13804–13805.
   PubMed Web of Science ®Google Scholar
• Palacios, D.S., et al., 2011. Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proceedings of the National Academy of Sciences of the United States of America, 108 (17), 6733–6738.
   PubMed Web of Science ®Google Scholar
• Paterson, P.J., et al., 2003. Treatment failure in invasive Aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. The Journal of Antimicrobial Chemotherapy, 52, 873–876.
   PubMed Web of Science ®Google Scholar
• Sherry, L., et al., 2017. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerging Infectious Diseases, 23 (2), 328–331.
   PubMed Web of Science ®Google Scholar
• Shimizu, K., et al., 2010. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. Journal of Controlled Release: Official Journal of the Controlled Release Society, 141, 208–215.
   PubMed Web of Science ®Google Scholar
• Stone, N.R.H., et al., 2016. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs, 76 (4), 485–500.
   PubMed Web of Science ®Google Scholar
• Takemoto, K., et al., 2006. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 57, 724–731.
   PubMed Web of Science ®Google Scholar